Echocardiographic heart ageing patterns predict cardiovascular and non-cardiovascular events and reflect biological age: the SardiNIA study.

Age-dependent diseases Ageing heart Biological age Cardiovascular disease Cardiovascular prevention Echocardiography

Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
18 Apr 2024
Historique:
received: 10 05 2023
revised: 04 07 2023
accepted: 28 07 2023
pmc-release: 01 08 2024
medline: 19 4 2024
pubmed: 1 8 2023
entrez: 1 8 2023
Statut: ppublish

Résumé

Age is a crucial risk factor for cardiovascular (CV) and non-CV diseases. As people age at different rates, the concept of biological age has been introduced as a personalized measure of functional deterioration. Associations of age with echocardiographic quantitative traits were analysed to assess different heart ageing rates and their ability to predict outcomes and reflect biological age. Associations of age with left ventricular mass, geometry, diastolic function, left atrial volume, and aortic root size were measured in 2614 healthy subjects. Based on the 95% two-sided tolerance intervals of each correlation, three discrete ageing trajectories were identified and categorized as 'slow', 'normal', and 'accelerated' heart ageing patterns. The primary endpoint included fatal and non-fatal CV events, and the secondary endpoint was a composite of CV and non-CV events and all-cause death. The phenotypic age of the heart (HeartPhAge) was estimated as a proxy of biological age. The slow ageing pattern was found in 8.7% of healthy participants, the normal pattern in 76.9%, and the accelerated pattern in 14.4%. Kaplan-Meier curves of the heart ageing patterns diverged significantly (P = 0.0001) for both primary and secondary endpoints, with the event rate being lowest in the slow, intermediate in the normal, and highest in the accelerated pattern. In the Cox proportional hazards model, heart ageing patterns predicted both primary (P = 0.01) and secondary (P = 0.03 to <0.0001) endpoints, independent of chronological age and risk factors. Compared with chronological age, HeartPhAge was 9 years younger in slow, 4 years older in accelerated (both P < 0.0001), and overlapping in normal ageing patterns. Standard Doppler echocardiography detects slow, normal, and accelerated heart ageing patterns. They predict CV and non-CV events, reflect biological age, and provide a new tool to calibrate prevention timing and intensity. Age is the main risk factor for cardiovascular (CV) disease. Since people age and develop diseases at very different rates, biological age has been proposed as a more accurate measure of the body’s functional decline. This study aimed to investigate the ageing rates of the heart and to assess their impact on CV events. The phenotypic age of the heart was also estimated as a proxy for biological age. Associations of age with Doppler echocardiographic parameters were analysed in a subgroup of 2614 clinically healthy subjects, part of a larger cohort of 3817 adults of both sexes.Three patterns of slow, normal, and accelerated ageing rates of the heart were detected. They predicted both CV and non-CV events, with different and progressively increasing event rates from the slow to the accelerated pattern. Compared with chronological age, the phenotypic (biological) age of the heart was 9 years younger in the slow pattern, 4 years older in the accelerated pattern, and comparable in the normal pattern.A standard Doppler echocardiogram is therefore able to detect three distinct heart ageing patterns, which reflect different biological susceptibilities to age-dependent diseases and provide a new tool for personalizing timeliness and intensity of prevention.

Autres résumés

Type: plain-language-summary (eng)
Age is the main risk factor for cardiovascular (CV) disease. Since people age and develop diseases at very different rates, biological age has been proposed as a more accurate measure of the body’s functional decline. This study aimed to investigate the ageing rates of the heart and to assess their impact on CV events. The phenotypic age of the heart was also estimated as a proxy for biological age. Associations of age with Doppler echocardiographic parameters were analysed in a subgroup of 2614 clinically healthy subjects, part of a larger cohort of 3817 adults of both sexes.Three patterns of slow, normal, and accelerated ageing rates of the heart were detected. They predicted both CV and non-CV events, with different and progressively increasing event rates from the slow to the accelerated pattern. Compared with chronological age, the phenotypic (biological) age of the heart was 9 years younger in the slow pattern, 4 years older in the accelerated pattern, and comparable in the normal pattern.A standard Doppler echocardiogram is therefore able to detect three distinct heart ageing patterns, which reflect different biological susceptibilities to age-dependent diseases and provide a new tool for personalizing timeliness and intensity of prevention.

Identifiants

pubmed: 37527539
pii: 7234933
doi: 10.1093/eurjpc/zwad254
pmc: PMC11025036
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

677-685

Subventions

Organisme : NIDA NIH HHS
ID : HHSN271201100005C
Pays : United States
Organisme : NIH HHS
ID : N01-AG-1-2109
Pays : United States
Organisme : NIA NIH HHS
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: None declared.

Références

Circ Cardiovasc Imaging. 2017 Feb;10(2):
pubmed: 28196797
ESC Heart Fail. 2020 Jun;7(3):1344-1361
pubmed: 32266776
EBioMedicine. 2017 Jul;21:29-36
pubmed: 28396265
Circulation. 2003 Jan 21;107(2):346-54
pubmed: 12538439
J Hypertens. 1995 Dec;13(12 Pt 2):1818-22
pubmed: 8903659
Circ Cardiovasc Imaging. 2009 May;2(3):191-8
pubmed: 19808592
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Elife. 2020 Feb 11;9:
pubmed: 32041686
Aging Cell. 2019 Feb;18(1):e12861
pubmed: 30488641
Am J Epidemiol. 2018 Mar 1;187(3):529-538
pubmed: 29020168
Front Genet. 2019 Mar 26;10:263
pubmed: 30972107
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Nat Rev Genet. 2018 Jun;19(6):371-384
pubmed: 29643443
N Engl J Med. 2020 Oct 1;383(14):1293-1296
pubmed: 32997905
Exp Gerontol. 2004 Sep;39(9):1423-9
pubmed: 15489066
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
J Am Coll Cardiol. 2020 Mar 3;75(8):919-930
pubmed: 32130928
Mol Cell. 2013 Jan 24;49(2):359-367
pubmed: 23177740
Circ Cardiovasc Imaging. 2017 Jan;10(1):
pubmed: 28093411
Sci Rep. 2020 Jul 1;10(1):10752
pubmed: 32612244
Ann N Y Acad Sci. 2022 Jan;1507(1):70-83
pubmed: 34498278
J Am Heart Assoc. 2018 Jun 1;7(11):
pubmed: 29858363
Nat Commun. 2020 Feb 24;11(1):939
pubmed: 32094358
Lancet. 2020 Oct 17;396(10258):1285-1306
pubmed: 32679112
Lancet Public Health. 2019 Mar;4(3):e159-e167
pubmed: 30851869
J Am Coll Cardiol. 1992 Jun;19(7):1550-8
pubmed: 1534335
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Am J Cardiol. 2014 Sep 15;114(6):921-7
pubmed: 25108304
Eur J Prev Cardiol. 2022 Feb 19;29(1):5-115
pubmed: 34558602
Nature. 2019 Jul;571(7764):183-192
pubmed: 31292558
Am J Cardiol. 1996 Jul 15;78(2):197-202
pubmed: 8712142
Hypertension. 2020 Nov;76(5):1616-1624
pubmed: 32895017

Auteurs

Antonello Ganau (A)

Department of Medicine, Surgery, and Pharmacy, University of Sassari, Via Istria12, 07100 Sassari, Italy, Italy.

Marco Orrù (M)

Armando Businco Hospital, Azienda Ospedaliera Brotzu, Cagliari 09047, Italy.

Matteo Floris (M)

Department of Biomedical Sciences, University of Sassari, Sassari 07100, Italy.
Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Pier Sergio Saba (PS)

Cardiac Thoracic Vascular Department, Azienda Ospedaliero Universitaria, Sassari 07100, Italy.

Federica Loi (F)

Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Padova 35128, Italy.

Giuseppe D Sanna (GD)

Cardiac Thoracic Vascular Department, Azienda Ospedaliero Universitaria, Sassari 07100, Italy.

Michele Marongiu (M)

Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Lenuta Balaci (L)

Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Niccolò Curreli (N)

Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Liana A P Ferreli (LAP)

Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Francesco Loi (F)

Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Marco Masala (M)

Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Guido Parodi (G)

Department of Medicine, Surgery, and Pharmacy, University of Sassari, Via Istria12, 07100 Sassari, Italy, Italy.

Alessandro P Delitala (AP)

Department of Medicine, Surgery, and Pharmacy, University of Sassari, Via Istria12, 07100 Sassari, Italy, Italy.

David Schlessinger (D)

Laboratory of Genetics & Genomics, NIH/National Institute of Ageing, Bethesda, MD, USA.

Edward Lakatta (E)

Laboratory of Cardiovascular Science, NIH/National Institute of Ageing, Bethesda, MD, USA.

Edoardo Fiorillo (E)

Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Francesco Cucca (F)

Department of Biomedical Sciences, University of Sassari, Sassari 07100, Italy.
Institute of Genetics and Biomedical Research, National Research Council, Monserrato, Cagliari 09042, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH